Today: 7 February 2026
Subscribe
Browse Category

NYSE:TPL News 17 December 2025 - 9 January 2026

Why Texas Pacific Land (TPL) stock is up today: oil climbs, insider filings add color

Why Texas Pacific Land (TPL) stock is up today: oil climbs, insider filings add color

Texas Pacific Land shares rose 1.5% to $307.38 in late morning trading Friday, extending a rebound after a 7.7% surge Thursday. The stock moved between $303.83 and $309.79 as oil prices climbed for a second day. Directors Donna E. Epps and Donald G. Cook each received 554 shares as part of board retainers, recent SEC filings show. U.S. payrolls rose by 50,000 in December and unemployment fell to 4.4%.
9 January 2026
··
Texas Pacific Land (TPL) Stock Jumps on Bolt Data Center Partnership as 3-for-1 Split Nears — News, Forecasts, and Fresh Analysis for Dec. 17, 2025

Texas Pacific Land (TPL) Stock Jumps on Bolt Data Center Partnership as 3-for-1 Split Nears — News, Forecasts, and Fresh Analysis for Dec. 17, 2025

December 17, 2025 — Texas Pacific Land Corporation (NYSE: TPL) stock surged Wednesday after the Permian Basin-focused landowner disclosed a strategic agreement tied to large-scale AI data center development in West Texas, a move that instantly reframed the TPL story from “royalties and water” to “royalties, water — and AI infrastructure optionality.” Texas Pacific Land Corporation+1 As of the latest available quote during Wednesday’s session, TPL shares traded around $882, up roughly 7% on the day, reflecting strong investor appetite for the new “land + power + water + compute” angle. Investing.com South Africa Below is what happened on 12/17/2025,
17 December 2025
·

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop